Silvercorp (SVM) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing earni ...

Core Viewpoint - Nurix Therapeutics, Inc. (NRIX) has seen a 2.3% increase in share price over the past four weeks, closing at $12.44, with analysts suggesting a potential upside of 143.4% based on a mean price target of $30.28 [1] Price Targets - The average of 18 short-term price targets ranges from a low of $16.00 to a high of $41.00, with a standard deviation of $6.49, indicating variability among estimates [2] - The lowest estimate suggests a 28.6% increase from the current price, while the highest estimate indicates a 229.6% upside [2] Analyst Consensus and Earnings Estimates - Analysts are optimistic about NRIX's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.7%, with two estimates moving higher and no negative revisions [12] Zacks Rank - NRIX currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Price Movement Guidance - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Scorpio Tankers (STNG) closed the last trading session at $41.85, gaining 4.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $62.71 indicates a 49.8% upside potential.The average comprises seven short-term price targets ranging from a low of $42.00 to a high of $75.00, with a standard deviation of $11.93. While the lowest estimate indicates an increase of 0.4% from the current pr ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Gray Media (GTN) .Gray Media currently has an average brokerage r ...

Core Viewpoint - Johnson & Johnson is currently under observation due to its stock performance and potential future direction, particularly in relation to earnings estimates and revenue growth [1][2]. Earnings Estimate Revisions - For the current quarter, Johnson & Johnson is expected to report earnings of $2.64 per share, reflecting a decrease of -6.4% year-over-year, with a slight increase of +0.5% in the Zacks Consensus Estimate over the last 30 days [5]. - The consensus earnings estimate for the current fiscal year is $10.62, indicating a growth of +6.4% from the previous year, with a minor adjustment of +0.1% in the last month [5]. - For the next fiscal year, the earnings estimate stands at $11, suggesting a growth of +3.6% compared to the prior year, with a recent increase of +0.2% [6]. - Johnson & Johnson holds a Zacks Rank 2 (Buy), indicating a favorable outlook based on earnings estimate revisions [7]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $22.77 billion, representing a year-over-year increase of +1.4% [11]. - For the current fiscal year, the revenue estimates are $91.19 billion and $94.24 billion, indicating growth rates of +2.7% and +3.4%, respectively [11]. Last Reported Results and Surprise History - In the last reported quarter, Johnson & Johnson achieved revenues of $21.89 billion, a year-over-year increase of +2.4%, and an EPS of $2.77, up from $2.71 a year ago [12]. - The company exceeded the Zacks Consensus Estimate for revenues by +1.26% and for EPS by +7.78% [12]. - Johnson & Johnson has consistently beaten consensus EPS and revenue estimates over the past four quarters [13]. Valuation - Johnson & Johnson is graded B in the Zacks Value Style Score, indicating it is trading at a discount compared to its peers [17].

Cipher Mining Inc. (CIFR) shares soared 15.9% in the last trading session to close at $5.68. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 42.7% gain over the past four weeks.The stock recorded this price hike in response to the increase in the price of Bitcoin, the world's largest cryptocurrency, over the past few days.This company is expected to post quarterly loss of $0.12 per share in its upcoming report, which represents a ...

Perimeter Solutions, SA (PRM) shares soared 8.5% in the last trading session to close at $15.27. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 13.5% gain over the past four weeks.Perimeter Solutions has opened a new PHOS-CHEK facility at McClellan Park in Sacramento, CA, one of world’s most advanced fire-retardant production facilities. Spanning an area of 110,000-square site will serve as a major hub for production and distrib ...

Ecovyst (ECVT) shares soared 9.2% in the last trading session to close at $8.3. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 'no gain, no loss' position over the past four weeks.Ecovyst shares rose after a Citi analyst raised the price target from $7.50 to $10.00 while maintaining a Buy rating. The analyst also updated estimates for Ecovyst, with second-quarter 2025 and full-year 2025 EBITDA estimates moving up 2% and 1%, resp ...

Personalis (PSNL) shares ended the last trading session 14.2% higher at $7.51. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 34.6% gain over the past four weeks.The sudden uptrend in the stock price can be attributed to the positive investor mindset regarding the continued growth in revenues from the sale of Personalis’ pharma tests and services, signifying increasing adoption of its technology.This provider of c ...

Company Overview - AirSculpt Technologies, Inc. (AIRS) shares increased by 8.7% to $5.25 in the last trading session, supported by higher-than-average trading volume [1] - The stock has gained 8.3% over the past four weeks, driven by stronger profitability and early success from its go-to-market strategy [1] Earnings Expectations - The company is projected to report quarterly earnings of $0.02 per share, reflecting a year-over-year decline of 77.8% [2] - Expected revenues are $45.64 million, which is a decrease of 10.5% compared to the same quarter last year [2] Earnings Estimate Revisions - The consensus EPS estimate for AirSculpt Technologies has been revised 100% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [3] - A strong correlation exists between earnings estimate revisions and near-term stock price movements, suggesting potential for further strength in AIRS [3] Industry Comparison - AirSculpt Technologies is classified under the Zacks Technology Services industry, which includes other companies like Ibotta (IBTA) [4] - Ibotta's consensus EPS estimate has remained unchanged at $0.18, representing a year-over-year increase of 113.6% [5] - Ibotta has a Zacks Rank of 3 (Hold), while AirSculpt Technologies holds a Zacks Rank of 2 (Buy) [4][5]